Loading clinical trials...
Loading clinical trials...
The purpose of this study is to see if it is safe and effective to give SU5416 to HIV-infected patients with AIDS-related Kaposi's sarcoma (KS). SU5416 may prevent the growth of KS tumors.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
SUGEN
NCT06627764 · Substance Abuse, Intimate Partner Violence (IPV), and more
NCT06694805 · HIV Infections
NCT04142047 · HIV, HIV Infections
NCT07428330 · Cervix Cancer, HIV Infections, and more
NCT05398185 · HIV Infections, Acquired Immune Deficiency Syndrome, and more
Norris Cancer Ctr / USC
Los Angeles, California
UCLA Care Ctr / Ctr for Hlth Sciences
Los Angeles, California
Saint Francis Mem Hosp / HIV Care Unit
San Francisco, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions